[1] Bommart S, Bourdin A, Makinson A, et al. Infectious chest complications in haematological malignancies[J]. Diagn Interv Imaging, 2013,94(2):193-201.
[2] Hemmert C, Ohana M, Jeung MY, et al. Imaging of lung transplant complications[J]. Diagn Interv Imaging, 2014,95(4):399-409.
[3] Denning DW. Invasive aspergillosis[J]. Clin Infect Dis, 1998,26(4):781-803.
[4] Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis:a clinical review[J]. Eur Respir Rev, 2011,20(121):156-174.
[5] Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis[J]. Eur Respir J, 2013,41(3):621-626.
[6] Godet C, Philippe B, Laurent F, et al. Chronic pulmonary aspergillosis:an update on diagnosis and treatment[J]. Respiration, 2014,88(2):162-174.
[7] Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis[J]. Thorax, 2015,70(3):270-277.
[8] Chabi ML, Goracci A, Roche N, et al. Pulmonary aspergillosis[J]. Diagn Interv Imaging, 2015,96(5):435-442.
[9] Hussien A, Lin CT. CT findings of fungal pneumonia with emphasis on aspergillosis[J]. Emerg Radiol, 2018,25(6):685-689.
[10] Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia:characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis[J]. Radiology, 1985,157(3):611-614.
[11] Brook O, Guralnik L, Hardak E, et al. Radiological findings of early invasive pulmonary aspergillosis in immune-compromised patients[J]. Hematol Oncol, 2009,27(2):102-106.
[12] Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia[J]. J Clin Oncol, 2001,19(1):253-259.
[13] Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis:kinetics of CT morphology and correlation with clinical findings and outcome[J]. AJR Am J Roentgenol, 2006,187(2):404-413.
[14] Chong S, Lee KS, Yi CA, et al. Pulmonary fungal infection:imaging findings in immunocompetent and immunocompromised patients[J]. Eur J Radiol, 2006,59(3):371-383.
[15] Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis[J]. Clin Microbiol Infect, 2015,21(7):684 e611-688.
[16] Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis:frequency and meaning of the "hypodense sign" on unenhanced CT[J]. Br J Radiol, 2005,78(932):697-703.
[17] Tragiannidis A, Roilides E, Walsh TJ, et al. Invasive aspergillosis in children with acquired immunodeficiencies[J]. Clin Infect Dis, 2012,54(2):258-267.
[18] Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis:rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016,47(1):45-68.
[19] Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients[J]. Curr Opin Infect Dis, 2011,24(4):309-314.
[20] Maziarz EK, Perfect JR. Cryptococcosis[J]. Infect Dis Clin North Am, 2016,30(1):179-206.
[21] Inaba A, Okada A, Yoshida T, et al. Disseminated cryptococcosis with rapidly growing lung nodules in an end-stage renal disease patient[J]. Intern Med, 2017,56(3):377-380.
[22] Xie X, Xu B, Yu C, et al. Clinical analysis of pulmonary cryptococcosis in non-HIV patients in south China[J]. Int J Clin Exp Med, 2015,8(3):3114-3119.
[23] Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome[J]. N Engl J Med, 1989,321(12):794-799.
[24] Xie LX, Chen YS, Liu SY, et al. Pulmonary cryptococcosis:comparison of CT findings in immunocompetent and immunocompromised patients[J]. Acta Radiol, 2015,56(4):447-453.
[25] Orsini J, Blaak C, Tam E, et al. Disseminated cryptococcal infection resulting in Acute Respiratory Distress Syndrome (ARDS) as the Initial Clinical Presentation of AIDS[J]. Intern Med, 2016,55(8):995-998.
[26] Yamakawa H, Yoshida M, Yabe M, et al. Correlation between clinical characteristics and chest computed tomography findings of pulmonary cryptococcosis[J]. Pulm Med, 2015,2015:703407.
[27] Yang R, Yan Y, Wang Y, et al. Plain and contrast-enhanced chest computed tomography scan findings of pulmonary cryptococcosis in immunocompetent patients[J]. Exp Ther Med, 2017,14(5):4417-4424.
[28] Hu Z, Chen J, Wang J, et al. Radiological characteristics of pulmonary cryptococcosis in HIV-infected patients[J]. PLoS One, 2017,12(3):e0173858.
[29] Henderson VJ, Hirvela ER. Emerging and reemerging microbial threats. Nosocomial fungal infections[J]. Arch Surg, 1996,131(3):330-337.
[30] Loeffler J, Stevens DA. Antifungal drug resistance[J]. Clin Infect Dis, 2003,36(Suppl 1):S31-41.
[31] Franquet T, Muller NL, Lee KS, et al. Pulmonary candidiasis after hematopoietic stem cell transplantation:thin-section CT findings[J]. Radiology, 2005,236(1):332-337.
[32] Kontoyiannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer:an autopsy study[J]. Clin Infect Dis, 2002,34(3):400-403.
[33] Yasuda Y, Tobino K, Asaji M, et al. Invasive candidiasis presenting multiple pulmonary cavitary lesions on chest computed tomography[J]. Multidiscip Respir Med, 2015,10(1):11.
[34] Arshad H, Garcia S, Khaja M. Case report of invasive, disseminated candidiasis with peripheral nodular cavitary lesions in the lung[J]. Respir Med Case Rep, 2017,20:34-37.
[35] Althoff Souza C, Muller NL, Marchiori E, et al. Pulmonary invasive aspergillosis and candidiasis in immunocompromised patients:a comparative study of the high-resolution CT findings[J]. J Thorac Imaging, 2006,21(3):184-189.
[36] Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006:overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database[J]. Clin Infect Dis, 2010,50(8):1091-1100.
[37] Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies:a 20-year autopsy study[J]. Mycoses, 2013,56(6):638-645.
[38] Nucci M, Marr KA. Emerging fungal diseases[J]. Clin Infect Dis, 2005,41(4):521-526.
[39] Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants:results of the SEIFEM B-2004 study——Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne[J]. Clin Infect Dis, 2007,45(9):1161-1170.
[40] Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis:Fusarium spp., Scedosporium spp. and others[J]. Clin Microbiol Infect, 2014,20 Suppl 3:27-46.
[41] Franquet T, Gimenez A, Hidalgo A. Imaging of opportunistic fungal infections in immunocompromised patient[J]. Eur J Radiol, 2004,51(2):130-138.
[42] Wahba H, Truong MT, Lei X, et al. Reversed halo sign in invasive pulmonary fungal infections[J]. Clin Infect Dis, 2008,46(11):1733-1737.
[43] Marom EM, Holmes AM, Bruzzi JF, et al. Imaging of pulmonary fusariosis in patients with hematologic malignancies[J]. AJR Am J Roentgenol, 2008,190(6):1605-1609.
[44] Sassi C, Stanzani M, Lewis RE, et al. Radiologic findings of[QX(Y12#] Fusarium pneumonia in neutropenic patients[J]. Mycoses, 2017,60(2):73-78.
[45] Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis[J]. Semin Respir Crit Care Med, 2011,32(6):693-702.
[46] Hibbett DS, Binder M, Bischoff JF, et al. A higher-level phylogenetic classification of the fungi[J]. Mycol Res, 2007,111(Pt 5):509-547.
[47] Yang J, Zhang J, Feng Y, et al. A case of pulmonary mucormycosis presented as Pancoast syndrome and bone destruction in an immunocompetent adult mimicking lung carcinoma[J]. J Mycol Med, 2019,29(1):80-83.
[48] Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis[J]. Clin Infect Dis, 2012,54(Suppl 1):S23-34.
[49] Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis:pathophysiology, presentation, and management[J]. Clin Microbiol Rev, 2005,18(3):556-569.
[50] Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis[J]. Med Mycol, 2018,56(suppl 1):93-101.
[51] Legouge C, Caillot D, Chretien ML, et al. The reversed halo sign:pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia[J]? Clin Infect Dis, 2014,58(5):672-678.
[52] Nam BD, Kim TJ, Lee KS, et al. Pulmonary mucormycosis:serial morphologic changes on computed tomography correlate with clinical and pathologic findings[J]. Eur Radiol, 2018,28(2):788-795.
[53] Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer[J]. Clin Infect Dis, 2005,41(1):60-66.
[54] Choo JY, Park CM, Lee HJ, et al. Sequential morphological changes in follow-up CT of pulmonary mucormycosis[J]. Diagn Interv Radiol, 2014,20(1):42-46.
[55] Godoy MC, Viswanathan C, Marchiori E, et al. The reversed halo sign:update and differential diagnosis[J]. Br J Radiol, 2012,85(1017):1226-1235.